Clinical Trials

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

NCT04837716 2026-02-19

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

12 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03896074 2026-02-09

BEAT

206 enrolled

Non-small-cell Lung Cancer Patients

NCT07244926 2025-11-24

Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer

31 enrolled

Phase 2 Active not recruiting

Lung Neoplasms

NCT05781308 2025-11-18

ADAPTABLE

156 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05588388 2025-11-17

BELIEVE

39 enrolled

Phase 1 Active not recruiting

Small Cell Lung Carcinoma

NCT04227028 2025-09-16

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

5 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07134413 2025-08-21

QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC

77 enrolled

NSCLC

NCT02681549 2025-08-07

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

41 enrolled 20 charts

CNSDermatologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT07083375 2025-07-24

QL1706

56 enrolled

Extensive Small Cell Lung Cancer

NCT07001618 2025-07-23

IMMUNOLIFE2

162 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06953843 2025-07-14

Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases

366 enrolled

NSCLC Stage IV Without EGFR/ALK Mutation

NCT07014215 2025-06-10

PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy

52 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04042558 2025-05-31

GFPC 06-2018

150 enrolled

DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung

NCT06839105 2025-05-31

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Phase 1 Recruiting

214 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Colorectal Neoplasms

NCT06401824 2025-05-06

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

25 enrolled

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04512430 2025-04-02

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Phase 2 Terminated

4 enrolled 9 charts

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04997382 2025-02-25

CLASSIC5

112 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00708448 2025-02-13

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

Phase 1 Completed

26 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06749860 2024-12-27

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

58 enrolled

Lung Neoplasms

NCT06728865 2024-12-11

Better Brain

70 enrolled

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT03872661 2024-12-06

NIBCUN

36 enrolled

Lung Neoplasms

NCT04973293 2024-11-19

Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Phase NA Recruiting

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05807893 2024-11-13

SUPER BRAIN

Phase 2/3 Completed

40 enrolled

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05468242 2024-10-30

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

116 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00309998 2024-10-29

Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

50 enrolled

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06537297 2024-09-20

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

30 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06557096 2024-08-16

CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

100 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplastic Cells, Circulating

NCT05055908 2024-08-02

BECOME

Phase 3 Recruiting

12,000 enrolled

Lung Neoplasms

NCT06492421 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

90 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04730999 2024-07-05

CeLEBrATE

54 enrolled

Small Cell Lung Carcinoma

NCT06483347 2024-07-03

Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT

90 enrolled

Lung Neoplasms

NCT05284539 2024-06-07

Awesome

760 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04322578 2024-06-04

CONFIRM

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05266846 2024-05-30

BEYOND

78 enrolled

Phase 2 Active not recruiting

Adenocarcinoma of Lung

NCT04147351 2024-04-16

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

22 enrolled

BreastGastrointestinalGynecologicThoracic

NSCLC Stage IIIB~IV

NCT06307249 2024-03-12

PTST_PALBEVA

Phase 1 Recruiting

50 enrolled

Breast Neoplasms, Inflammation, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT04310943 2024-03-06

Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma

24 enrolled

Adenocarcinoma of Lung

NCT04238169 2024-02-28

Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06229340 2024-01-29

NТО-RAS

DermatologicGastrointestinalThoracic

20 enrolled

Lung Neoplasms, Melanoma, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05296278 2024-01-10

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03647592 2023-12-27

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

Unknown

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06182800 2023-12-27

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

Phase 2 Unknown

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04099836 2023-12-26

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Phase 2 Terminated

7 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT02803203 2023-09-22

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Phase 1/2 Completed

49 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04345146 2023-08-28

Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC

100 enrolled

BreastGastrointestinalGynecologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05431582 2023-06-15

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Phase 1 Withdrawn

Breast Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

Phase 2/3 Terminated

36 enrolled 14 charts

EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT03991403 2023-04-03

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Phase 3 Unknown

228 enrolled